You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 7, 2025

Details for Patent: 10,286,029


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,286,029 protect, and when does it expire?

Patent 10,286,029 protects MAVYRET and is included in two NDAs.

Protection for MAVYRET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and ten patent family members in twenty-six countries.

Summary for Patent: 10,286,029
Title:Method for treating HCV
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
Inventor(s): Awni; Walid M. (Green Oaks, IL), Bernstein; Barry M. (Mequon, WI), Campbell; Andrew L. (Lake Forest, IL), Dutta; Sandeep (Lincolnshire, IL), Lin; Chih-Wei (Vernon Hills, IL), Liu; Wei (Mundelein, IL), Menon; Rajeev M. (Buffalo Grove, IL), Podsadecki; Thomas J. (Chicago, IL), Wang; Tianli (Lake Bluff, IL), Mensing; Sven (Mannheim, DE)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:14/676,370
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,286,029: A Detailed Analysis

Introduction

United States Patent 10,286,029, titled "Method for treating HCV," is a significant patent owned by AbbVie Inc., focusing on interferon-free therapies for the treatment of Hepatitis C Virus (HCV). This article delves into the scope, claims, and the broader patent landscape surrounding this patent.

Overview of the Patent

Patent Title and Number

The patent, numbered US10286029B2, is titled "Method for treating HCV" and was granted to AbbVie Inc.[4].

Publication and Grant Dates

The patent was published on March 19, 2019, and granted on the same date, following the patent application filed on July 14, 2014[4].

Scope of the Patent

Interferon-Free Therapies

The patent describes methods for treating HCV using interferon-free therapies, which are preferred for their shorter treatment duration. This approach is a significant advancement in HCV treatment, offering patients a more manageable and effective treatment regimen[4].

Active Ingredients and Compounds

The patent details specific compounds and their combinations used in the treatment. These include macrocyclic proline-derived HCV serine protease inhibitors and other anti-viral compounds. The precise chemical structures and formulations are critical to the patent's scope[4].

Claims of the Patent

Independent and Dependent Claims

The patent includes both independent and dependent claims. Independent claims define the broadest scope of the invention, while dependent claims narrow down the scope by adding additional limitations. For example, Claim 1 might describe a general method for treating HCV, while dependent claims might specify particular dosages or treatment durations[4].

Claim Language and Metrics

The claim language is crucial in defining the patent's scope. Metrics such as independent claim length and independent claim count can be used to measure patent scope. Research suggests that narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].

Patent Landscape

Patent Expiry Dates

The patent is part of a larger portfolio of patents protecting Mavyret, a drug owned by AbbVie Inc. The expiry dates for these patents range from 2030 to 2035, with the patent in question expiring in March 2034[1].

Legal Activities and Patent Maintenance

The patent's life can be affected by various legal activities such as maintenance fee payments, certificate of corrections, and opposition proceedings. For instance, recent activities include the payment of maintenance fees and post-issue communications[1].

Opposition and Litigation

The patent is subject to opposition proceedings, particularly in European jurisdictions. For example, oppositions filed by Generics (U.K.) Limited are ongoing, which could impact the patent's validity and expiry dates[1].

Impact on Generic Launch

Patent Expiry and Generic Availability

The expiry of the patent and related patents will pave the way for generic versions of the drug. However, the exact timing can be influenced by legal activities and oppositions. Tracking these activities is crucial for predicting when generics might enter the market[1].

Market Implications

The availability of generic versions can significantly impact the market, reducing costs for patients and increasing competition. This can also drive innovation as companies may focus on developing new treatments rather than relying on existing patents[1].

Measuring Patent Scope

Independent Claim Length and Count

Research has shown that metrics such as independent claim length and count can provide insights into patent scope. These metrics can help in understanding the breadth and clarity of the patent claims, which in turn affect the patent's validity and enforcement[3].

Forward Citations and Patent Maintenance

Forward citations and patent maintenance payments are also indicators of patent scope. Patents with narrower claims tend to have more forward citations and require fewer maintenance payments, suggesting a more focused and valuable invention[3].

Practical Considerations

Licensing and Litigation

The scope and claims of the patent can influence licensing and litigation strategies. Broader patents may lead to more licensing and litigation costs, while narrower patents may offer clearer boundaries and less legal complexity[3].

Innovation Incentives

The clarity and breadth of patent claims can affect innovation incentives. Patents with well-defined claims can encourage innovation by providing clear boundaries and reducing the risk of litigation[3].

Key Takeaways

  • Patent Scope and Claims: The patent's scope is defined by its claims, with independent claims setting the broadest boundaries and dependent claims adding specificity.
  • Legal Activities: The patent's life and validity can be influenced by legal activities such as maintenance fees, corrections, and oppositions.
  • Market Impact: The expiry of the patent will allow for generic versions, impacting market competition and patient costs.
  • Metrics for Patent Scope: Independent claim length and count, forward citations, and patent maintenance payments are useful metrics for understanding patent scope.

FAQs

What is the main focus of United States Patent 10,286,029?

The main focus of United States Patent 10,286,029 is on methods for treating Hepatitis C Virus (HCV) using interferon-free therapies.

When does the patent expire?

The patent is set to expire in March 2034, although this date may change based on legal activities.

How do legal activities affect the patent's life?

Legal activities such as maintenance fee payments, certificate of corrections, and opposition proceedings can extend or shorten the patent's life.

What are the implications of the patent's expiry for generic drugs?

The expiry of the patent will allow generic versions of the drug to enter the market, potentially reducing costs for patients and increasing competition.

How can the scope of the patent be measured?

The scope of the patent can be measured using metrics such as independent claim length and count, forward citations, and patent maintenance payments.

Sources

  1. Pharsight: Mavyret patent expiration - Pharsight
  2. USPTO: Patent Claims Research Dataset
  3. SSRN: Patent Claims and Patent Scope
  4. Google Patents: US10286029B2 - Method for treating HCV
  5. ACUS: U.S. Patent Small Claims Court

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,286,029

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie MAVYRET glecaprevir; pibrentasvir PELLETS;ORAL 215110-001 Jun 10, 2021 RX Yes Yes 10,286,029*PED ⤷  Try for Free Y ⤷  Try for Free
Abbvie MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes 10,286,029*PED ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.